Correvio Pharma is engaged in the discovery, development and commercialization of drugs to treat or prevent cardiovascular diseases. Co.'s product, BRINAVESS™, is approved for marketing in the European Union, Iceland and Norway for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. Co.'s clinical programs are also focused on the treatment of atrial fibrillation, an arrhythmia (or abnormal rhythm) of the upper chambers of the heart. Co. also has a few pre-clinical projects directed at various therapeutic indications that focus on modulating cellular proteins (ion channels) for cardiac diseases.